Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

IBN scientists harness ultrasmall peptides to repair spinal disc damage

New ultrasmall peptides that can be used as building blocks for a wide range of regenerative applications such as spinal disc replacement and cartilage repair have been developed by scientists at the Institute of Bioengineering and Nanotechnology (IBN), the world's first bioengineering and nanotechnology research institute. These peptides spontaneously assemble in water to form hydrogels, which resemble collagen, a major component of connective tissues found in cartilage, ligaments, tendons, bone and skin.

12 Sep 2011

USC team produces world's first high-resolution images of α7 neuroreceptor

For the first time, USC scientists have mapped out a neuroreceptor. This scientific breakthrough promises to revolutionize the engineering of drugs used to treat ailments such as Alzheimer's disease and schizophrenia.

12 Sep 2011

Work intensity of physicians across several specialties is fairly equal: Study

Contrary to longstanding assumptions, new findings suggest the work intensity of physicians across several specialties is fairly equal. The study, funded by the American Academy of Neurology along with several other medical associations and published online ahead of print in the journal Medical Care, provides the groundwork for the development of a more reliable, scientific measurement of physician work intensity that may guide future national policy in patient safety, practice management and payment.

12 Sep 2011

Roche initiates Phase 1 clinical trial of investigational drug for Down syndrome

Roche today announced the initiation of its first Phase 1 clinical trial to investigate the safety and tolerability of a molecule designed to address the cognitive and behavioral deficits associated with Down syndrome.

12 Sep 2011

Simple universal test to detect Alzheimer’s early

A ten-minute memory test that gives early warning of Alzheimer’s in people as young as 50 is being piloted in GP surgeries. Using a touch-screen computer or an iPad, it can distinguish between normal forgetfulness and the more dangerous memory lapses that signal dementia in its earliest stages. If trials are successful, it could be in widespread use in under a year. The developer, Cambridge Cognition, said the mobile electronic test will allow GPs to access patients presenting memory problems more quickly, simply and accurately than with tradition paper-based tests.

8 Sep 2011

MSTAR Program fosters interest in geriatric medicine and research

"This year marks the first year that the oldest members of the Baby Boomer generation turns 65. This milestone is an indication of the upcoming increase of older adults in the American population, and accompanying it will be an increase in their complex medical needs. We currently have a shortage of physicians specializing in geriatric medicine, leaving a gap that needs to be filled." states Stephanie Lederman, Executive Director of The American Federation for Aging Research.

8 Sep 2011

Pharnext puts together €2.5M to fund development of Pleodrug for Charcot-Marie-Tooth disease

Pharnext SAS, a biopharmaceutical company specializing in the development of innovative treatments based on Pleotherapy for severe neurological diseases, today announced that it has put together a €2.5 million round of financing (corresponding to a pre-money company valuation of €60 million).

8 Sep 2011

Running may trigger the production of new brain cells throughout life, research shows

Researchers have, for the first time, isolated exercise as the key factor in triggering the production of functional new cells in the learning and memory centre of the brain.

7 Sep 2011

Month of birth may determine career

Being born in a certain month appears to indicate the statistical likelihood of what job a person will end up with, the study by the UK’s Office for National Statistics has found.

6 Sep 2011

European Neurotech Investing & Partnering Summit to take place in Helsinki

The inaugural European Neurotech Investing & Partnering Summit takes place in Helsinki this week. It features keynotes on the state of the European neurotech industry, investor analysis, as well as company and research project presentations on next generation treatments emerging in the EU for unmet needs of brain and nervous system disorders like Alzheimer's, addiction, depression, schizophrenia, Parkinson's, Huntington's, stroke and more.

6 Sep 2011

Psychogenic non-epileptic seizures may go undiagnosed for longer in veterans

Psychogenic non-epileptic seizures may go undiagnosed for much longer in veterans compared to civilians, according to a new study published in the September 6, 2011, print issue of Neurology, the medical journal of the American Academy of Neurology.

6 Sep 2011

Moderate to severe cognitive impairment has impact on life expectancy

Cognitive impairment, even when detected at an early, mild stage, is a significant predictor of decreased life expectancy.

6 Sep 2011

DiaGenic allots options to employees

According to the resolution by the Annual General Meeting on 23 May 2011, the Board of Directors in DiaGenic ASA today allotted options to DiaGenic employees. The share options have strike price of NOK 6.00 per share, which is set based on last week weighted share price + 10%. The options have life of 4 years and can be exercised after 3 years.

5 Sep 2011

Freiburg researchers receive European Research Council Starting Grants

Marta Artal Sanz, Thomas Brox, Winfried Römer, and Oliver Schilling from the University of Freiburg have been selected for one of the most prestigious European grants for young researchers: The European Research Council (ERC) has awarded them a total of 5.8 million euros in ERC Starting Grants for new projects.

2 Sep 2011

Blocked blood vessels linked to familiar signs of aging

Many common signs of aging, such as shaking hands, stooped posture and walking slower, may be due to tiny blocked vessels in the brain that can't be detected by current technology.

2 Sep 2011

AAN calls all high school coaches, athletes and parents to learn signs of sports concussion

The American Academy of Neurology, the leading group of neurologists dedicated to managing sports concussion, is issuing a call to all youth and high school coaches, athletes and parents to learn the signs of sports concussion and to know when a player must leave the game.

2 Sep 2011

Valproic acid may increase survival for brain tumor patients

New research suggests brain tumor patients who take the seizure drug valproic acid on top of standard treatment may live longer than people who take other kinds of epilepsy medications to control seizures.

2 Sep 2011

People with Alzheimer's have lower ubiquilin-1 protein levels

Researchers have found that a protein variation linked by some genetic studies to Alzheimer's disease is consistently present in the brains of people with Alzheimer's.

2 Sep 2011

Two ALS-associated genes work in tandem to support long-term survival of motor neurons

Although several genes have been linked to amyotrophic lateral sclerosis (ALS), it is still unknown how they cause this progressive neurodegenerative disease. In a new study, Columbia University Medical Center (CUMC) researchers have demonstrated that two ALS-associated genes work in tandem to support the long-term survival of motor neurons.

2 Sep 2011

CWRU, NeoProteomics sign licensing deal for four bioinformatics software programs

Case Western Reserve University and NeoProteomics Inc. have announced the university's licensing of four software programs designed to improve understanding of biology at a complex molecular level for improved treatment of cancers and various other diseases.

31 Aug 2011